Adagio Medical
Developing innovative cryoablation technologies that create continuous, linear, transmural lesions to treat cardiac arrhythmias, including paroxysmal and persistent atrial fibrillation.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD232—348m (Dealroom.co estimates Nov 2020.)
Laguna Hills California (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $2.5m | Seed | |
| N/A | $4.1m | Early VC | |
| N/A | $7.0m | Early VC | |
$42.5m | Series E | ||
* | N/A | $9.5m | Debt |
* | $130m | SPAC IPO | |
| Total Funding | CAD76.5m | ||
Related Content
Recent News about Adagio Medical
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.